Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis
Paul Guedeney(Université Paris Cité), Gilles Montalescot(Maastricht University Medical Centre), Roxana Mehran(Mount Sinai Hospital), Silvy Laporte(Centre Hospitalier Universitaire de Saint-Étienne), Sabato Sorrentino(Magna Graecia University), Birgit Vogel(Cardiovascular Institute of the South), Deborah N. Kalkman(Cardiovascular Institute of the South), Salvatore De Rosa(Magna Graecia University), Johanne Silvain(Sorbonne Université), Édouard Ollier(Centre Hospitalier Universitaire de Saint-Étienne), Gennaro Giustino(Cardiovascular Institute of the South), Jean‐Philippe Collet(Sorbonne Université), Benoît Lattuca(Johnson University), Michel Zeitouni(Sorbonne Université), Ciro Indolfi(University of Calabria), Céline Chapelle(Inserm), Anton Camaj(Columbia University Irving Medical Center), Mathieu Kernéis(Sorbonne Université), Bimmer E. Claessen(Columbia University Irving Medical Center)
Cited by 61
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
|European Heart Journal|2020|5k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k